Inhibition of HIV-1 replication using d-amino acid peptides

Details Inhibition of HIV-1 replication using d-amino acid peptides Inhibition of HIV-1 replication using d-amino acid peptides

1999-10-01

2002-10-22

Cochrane Carlson, Karen (Department: 1653)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S012200, C514S014800, C514S015800, C514S016700, C514S018700, C530S324000, C530S327000, C530S328000, C530S329000, C530S334000, C530S331000, C530S344000, C435S235100

Reexamination Certificate

active

06468969

ABSTRACT:

BACKGROUND OF THE INVENTION
RNA-protein interactions are important in many cellular functions, including transcription. RNA splicing, and translation. One example of such an interaction is the mechanism of trans-activation of the human immunodeficiency virus type 1 (HIV-1) gene expression that requires the interaction of Tat protein with the trans-activation responsive region (TAR) RNA, a 59-base stem-loop structure located at the 5′-end of all nascent HIV-1 transcripts
1
.
The promoter of HIV-1, located in the U3 region of the viral long terminal repeat (LTR), is an inducible promoter which can be stimulated by the trans-activator protein, Tat
1
. As in other lentiviruses, Tat protein is essential for trans-activation of viral gene expression
2-6
.
Tat-derived peptides containing the arginine-rich RNA-binding domain of Tat are able to form in vitro complexes with TAR RNA
7-14
. Structural studies of Tat protein show that the RNA-binding domain is not a rigid helix
15
. Since the RNA-binding domain of Tat has a flexible structure, the symmetry of small peptides containing arginine-rich sequences may not be crucial in TAR RNA recognition. Recent syntheses of two D-enantiomeric proteins demonstrated that these proteins have optical properties, substrate specificity
16
, and a structure
17,13
that mirrors those of the naturally occurring L-proteins. A powerful method to identify D-peptide ligands through mirror-image phage display has been recently discovered and a cyclic D-peptide was identified that interacts with the Src homology 3 domain of c-Src
19
. Due to the difference in chirality, D-peptides are resistant to proteolytic degradation and cannot be efficiently processed for major histocompatibility complex class II-restricted presentation to T helper cells (T
H
cells). Consequently, D-peptides would not induce a vigorous humoral immune response that impairs the activity of L-peptide drugs
20
.
SUMMARY OF THE INVENTION
The present invention concerns Tat-inhibitory polypeptide derivatives. More particularly, this invention relates to polypeptides of the formula I
D-Cys-D-Phe-D-Thr-D-Thr-D-Lys-D-Ala-D-Leu-D-Gly-D-Ile-D-Ser-D-Tyr-D-Gly-D-Arg-D-Lys-D-Lys-D-Arg-D-Arg-D-Gln-D-Arg-D-Arg-D-Arg-D-Pro-D-Pro-D-Gln-D-Gly-D-Ser-D-Gln-D-Thr-D-His-D-Gln-D-Val-D-Ser-D-Leu-D-Ser-D-Lys-D-Gln (SEQ ID 1)
and fragments and analogs thereof, and the biologically and pharmaceutically acceptable salts thereof, which exhibit advantageous properties, including binding to &Dgr;TAR, inhibition of LTR-dependent reporter gene expression in a model cell assay and, finally, inhibition of HIV-1 replication, as determined in assays of HIV-induced syncytium formation, cytotoxicity and reverse transcriptase production. These compounds are thus useful in the treatment of HIV-1 infection by virtue of their ability to block the interaction of Tat protein with TAR RNA, thereby interfering with the transactivation step in the replication cycle of HIV-1. The rationale for this approach is that such peptides compete with the full length Tat protein for binding to TAR RNA, thereby preventing the required interactions between other domains in Tat protein and the nascent transcription apparatus.
It is an object of the present invention to provide compounds which are useful in the treatment of HIV-1 by virtue of their ability to block the interaction of Tat protein with TAR RNA, thereby interfering with the trans activation step in the replication cycle of this virus.
It is further an object of this invention to provide pharmaceutical compositions suitable for the administration of such compounds.
It is a still further object of the present invention to provide a method of treating HIV-1 infection in mammals which comprises the administration of the compounds of the present invention.


REFERENCES:
patent: 5079231 (1992-01-01), Brunetti et al.
patent: 5225400 (1993-07-01), Brunetti et al.
patent: 5492896 (1996-02-01), Häbich et al.
patent: 5646120 (1997-07-01), Sumner-Smith
patent: 5767083 (1998-06-01), Abajian et al.
patent: WO 86/04334 (1986-07-01), None
patent: WO-8912461 (1989-12-01), None
patent: WO 96/22760 (1996-08-01), None
patent: WO97/12907 (1997-04-01), None
patent: WO98/47913 (1998-10-01), None
Huq, et al. Nature Structural Biology 4:881-882 (1997).

Affiliated with

Also associated with

Rating

Inhibition of HIV-1 replication using d-amino acid peptides does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Inhibition of HIV-1 replication using d-amino acid peptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibition of HIV-1 replication using d-amino acid peptides will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2970159